T. Rowe Price Associates
MIRM icon

T. Rowe Price Associates’s Mirum Pharmaceuticals MIRM Stock Holding History

T. Rowe Price Associates’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159M Buy
1,717,421
+297,046
+21% +$27.9M 0.02% 511
2025
Q4 		$112M Buy
1,420,375
+137,087
+11% +$9.84M 0.01% 604
2025
Q3 		$94.1M Sell
1,283,288
-133,927
-9% -$8.51M 0.01% 636
2025
Q2 		$72.1M Buy
1,417,215
+2,078
+0.1% +$92.5K 0.01% 643
2025
Q1 		$63.8M Sell
1,415,137
-7,592
-0.5% -$358K 0.01% 647
2024
Q4 		$58.8M Buy
1,422,729
+138,623
+11% +$5.78M 0.01% 706
2024
Q3 		$50.1M Buy
1,284,106
+84,886
+7% +$3.39M 0.01% 754
2024
Q2 		$41M Sell
1,199,220
-398,286
-25% -$10.4M ﹤0.01% 782
2024
Q1 		$40.1M Buy
1,597,506
+432,824
+37% +$11.9M ﹤0.01% 779
2023
Q4 		$34.4M Buy
1,164,682
+1,132,723
+3,544% +$34.3M ﹤0.01% 804
2023
Q3 		$1.01M Sell
31,959
-67,722
-68% -$1.85M ﹤0.01% 1795
2023
Q2 		$2.58M Buy
99,681
+87,753
+736% +$2.33M ﹤0.01% 1392
2023
Q1 		$287K Sell
11,928
-4,903
-29% -$112K ﹤0.01% 2366
2022
Q4 		$328K Buy
16,831
+4,800
+40% +$94.9K ﹤0.01% 2339
2022
Q3 		$253K Buy
+12,031
New +$290K ﹤0.01% 2456

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates's MIRM Position: Q1 2026 in Review

T. Rowe Price Associates increased its Mirum Pharmaceuticals (MIRM) stake by 21% in Q1 2026, buying an estimated $27.9M and bringing the position to 1,717,421 shares worth $159M. The position accounts for 0.02% of the portfolio, ranked #511.

T. Rowe Price Associates first reported a position in MIRM in Q3 2022 and has held it in 15 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • T. Rowe Price Associates held 1,717,421 shares of Mirum Pharmaceuticals worth $159M as of Q1 2026.
  • T. Rowe Price Associates bought 297,046 Mirum Pharmaceuticals shares in Q1 2026, an estimated $27.9M.
  • Mirum Pharmaceuticals made up 0.02% of T. Rowe Price Associates's portfolio in Q1 2026, its #511 holding.
  • T. Rowe Price Associates first reported a position in Mirum Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.